Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2021
February 2021, Vol 12, No 1 | Payers’ Perspectives In Oncology: ASH 2020 Highlights
February 2021, Vol 12, No 1
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
By
Chase Doyle
Emerging Therapies
February 2021, Vol 12, No 1
Results of a phase 1 clinical trial showed that approximately 66% of patients with chronic-phase chronic myeloid leukemia (CML) had a major cytogenetic response (MCyR) to the novel oral
BCR-ABL1
tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they previously received ponatinib therapy. Jorge E. Cortes, MD, Director, Georgia Cancer Center, Augusta University, presented the results at ASH 2020.
Read More
Pevonedistat plus Azacitidine Combination Improves Outcomes versus Azacitidine Monotherapy in High-Risk Myelodysplastic Syndromes
By
Wayne Kuznar
Myelodysplastic Syndromes
February 2021, Vol 12, No 1
The investigational drug pevonedistat in combination with azacitidine injection (Vidaza) leads to longer event-free survival (EFS) and a higher complete response rate than azacitidine alone in patients with high-risk myelodysplastic syndromes (MDS), according to results from a phase 2, open-label, international clinical trial. The findings were presented by Mikkael A. Sekeres, MD, MS, Director, Leukemia Program, Cleveland Clinic, OH, at ASH 2020.
Read More
Financial Toxicity Intervention in Patients with Hematologic Malignancies Effective, Improves Adherence and Quality of Life
By
Chase Doyle
Value-Based Care
February 2021, Vol 12, No 1
The use of a screening method followed by a financial toxicity intervention that involves navigators, pharmacists, and financial counselors demonstrated significantly improved quality of life for patients with hematologic malignancies, said lead investigator Thomas Greg Knight, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, at ASH 2020.
Read More
Pembrolizumab Shows Long-Term Benefits in Metastatic Colorectal Cancer and MSI-H or dMMR
Colorectal Cancer
,
In the Literature
February 2021, Vol 12, No 1
Chemotherapy is currently the standard of care for patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC); however, some patients have disease that is refractory to chemotherapy.
Read More
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
By
Chase Doyle
Lymphoma
February 2021, Vol 12, No 1
Interim analysis of the phase 2 clinical trial of chimeric antigen receptor (CAR) T-cell therapy as first-line treatment of patients with high-risk large B-cell lymphoma shows that axicabtagene ciloleucel (Yescarta) has substantial benefit in patients with unmet medical needs.
Read More
Bispecific Antibodies in Phase 1 Studies Show Promising Efficacy in Heavily Pretreated Patients with Multiple Myeloma
By
Wayne Kuznar
Multiple Myeloma
February 2021, Vol 12, No 1
Bispecific antibodies are showing promise in patients with hematologic malignancies, notably relapsed or refractory multiple myeloma. Results from studies of 3 bispecific antibodies were presented at ASH 2020, showing deep and durable responses.
Read More
Belantamab Induces Deep Responses in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
By
Wayne Kuznar
Multiple Myeloma
February 2021, Vol 12, No 1
A post-hoc analysis of a pivotal clinical trial presented at ASH 2020 showed that the recently approved belantamab mafodotin-blmf (Blenrep), a first-in-class antibody targeting BCMA (B-cell maturation antigen), induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. This analysis of the ongoing, open-label DREAMM-2 study focused on 1-year outcomes based on the number of previous therapies. The results were presented by Sagar Lonial, MD, FACP, Chief Medical Officer, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
Read More
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma